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Abstract Serum anti-mitochondrial antibodies (AMA) are
the serological hallmark of primary biliary cirrhosis (PBC),
yet up to 15% of PBC sera are AMA negative at routine
indirect immunofluorescence (IIF) while being referred to
as “probable” cases. The diagnostic role of PBC-specific
antinuclear antibodies (ANA) remains to be determined. We
will report herein data on the accuracy of new laboratory
tools for AMA and PBC-specific ANA in a large series of
PBC sera that were AMA-negative at IIF. We will also
provide a discussion of the history and current status of
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AMA detection methods. We included IIF AMA-negative
PBC sera (n=100) and sera from patients with other
chronic liver diseases (n=104) that had been independently
tested for IIF AMA and ANA; sera were blindly tested with
an ELISA PBC screening test including two ANA
(gp210, sp100) and a triple (pMIT3) AMA recombinant
antigens. Among IIF AMA-negative sera, 43/100 (43%)
manifested reactivity using the PBC screening test. The
same test was positive for 6/104 (5.8%) control sera. IIF
AMA-negative/PBC screen-positive sera reacted against
pMIT3 (11/43), gp210 (8/43), Sp100 (17/43), both
pMIT3 and gp210 (1/43), or both pMIT3 and Sp100
(6/43). Concordance rates between the ANA pattern on
HEp-2 cells and specific Sp100 and gp210 ELISA results
in AMA-negative subjects were 92% for nuclear dots and
Sp100 and 99% for nuclear rim and gp210. Our data
confirm the hypothesis that a substantial part of IIF
AMA-negative (formerly coined “probable”) PBC cases
manifest disease-specific autoantibodies when tested
using newly available tools and thus overcome the
previously suggested diagnostic classification. As sug-
gested by the recent literature, we are convinced that the
proportion of AMA-negative PBC cases will be signifi-
cantly minimized by the use of new laboratory methods
and recombinant antigens.
Keywords Autoimmune cholangitis . Nuclear dots . Rim
like . Recombinant antigens . Diagnostic accuracy
Serum AMA in Clinical Practice
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
disease in which biliary epithelial cells within the intra-
hepatic bile ducts are targeted by an immune-mediated
injury, ultimately leading to liver fibrosis and cirrhosis [1].
PBC shares with other autoimmune diseases a striking
female predominance [2], increased familial risk with a
prevalence approaching 6% in relatives of index cases [3],
and the incomplete concordance in monozygotic twins [4].
As internationally accepted, the diagnosis of PBC is based
on the fulfillment of two out of three criteria: i.e., elevation
of alkaline phosphatase, compatible histology, and serum
anti-mitochondrial antibodies (AMA) [5]. Serum AMA is
the major hallmark of PBC and is considered direct proof of
the autoimmune pathogenesis of the disease. Despite
manifesting among the highest disease sensitivity and
specificity rates compared to other autoantibodies, there
remains a subgroup of patients with undetectable AMA
using routine methods [6]. Further, numerous studies
suggested that AMA can appear before other histological
or biochemical signs of liver injury [7] while AMA-positive
subjects are expected to develop a clinical PBC profile in
the subsequent years [8, 9]. A classification proposed by a
British group [10] included a “probable” diagnosis when
two out of the three criteria (most often AMA positivity and
compatible liver histology in the presence of normal liver
enzymes) are present while a “definite” diagnosis is made
only in the presence of all three. This classification may be
seen as strict since the vast majority of asymptomatic
AMA-positive individuals (particularly when serum reac-
tivities are found using sensitive and specific methods) will
eventually develop a classic picture of PBC during follow-
up. Moreover, patients lacking detectable AMA, especially
when indirect immunofluorescence (IIF) is used but otherwise
presenting signs and symptoms of PBC should be regarded as
affected by “AMA-negative PBC” (or autoimmune cholangi-
tis) as they appear to follow a similar natural history when
compared to their AMA-positive counterparts [6].
Based on these observations, it is obvious that developing a
most sensitive and specific tool to determine serumAMA is of
great importance in the diagnosis and management of patients
with PBC. During routine tests, AMA are detected using IIF
on frozen sections of mouse liver, stomach, and kidney in
approximately 85% of PBC cases, thus not allowing an
accurate diagnosis in a subgroup of patients. One major
advancement in the serum diagnosis of PBC followed the
cloning of the AMA autoantigens as three members of the 2-
oxo-acid dehydrogenase complex family [11] and the
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development of a triple-expression hybrid clone coined
pMIT3 [12]. Besides AMA, multiple serum autoantibodies
may be detected with lower frequencies in patients with PBC
[13] along with a specific cytokine milieu [14]. In PBC sera,
nondisease-specific ANA, particularly with a homogeneous,
speckled and anti-centromere pattern at IIF [15] are detected
in a subgroup of patients while the multiple nuclear dot and
rim-like/membranous IIF patterns are highly specific for PBC.
This is of particular importance for AMA-negative PBC cases
as longitudinal data from different populations have con-
firmed the prognostic role of PBC-specific ANA [16, 17].
Interestingly, novel serum markers have been recently
proposed for PBC [18, 19], yet their clinical significance
and diagnostic impact remain elusive. To overcome these
limitations and the scarcity of AMA-negative sera in a rare
condition such as PBC, the Study Group on Autoimmune
Diseases of the Italian Society of Laboratory Medicine
collected PBC sera without detectable AMA at IIF to
determine whether commercially available tests using recom-
binant mitochondrial and nuclear antigens could prove helpful
in the diagnosis of IIF–AMA-negative cases. Our data
confirm that new diagnostic tools significantly increase
AMA and ANA sensitivity rates in this challenging subgroup
of patients, as recently reported [20]. These results will be
illustrated in this article along with a discussion of the current
status of serum tests in PBC diagnosis and management.
PBC Screening Tests in AMA-Negative PBC Sera
Patients and Methods
Sera from PBC patients (n=100) without detectable AMA
at IIF were specifically obtained from 15 Italian referral
centers between December 2006 and March 2008. In all
cases, the diagnosis of PBC was based on the fulfillment
of the other two internationally accepted criteria [5] and all
patients had one liver biopsy performed during follow-up for
diagnosis purposes. In 79 cases the liver biopsy was
performed within 18 months of blood sampling and staging
was arrayed in all cases: 17/79 (22%) had stage I disease, 37
(47%) stage II, 16 (20%) stage III, and nine (11%) stage IV
according to Ludwig’s criteria [21]. Among PBC cases, 90/
100 (90%) were females with a median age of 61 years
(range 37–89); other clinical and biochemical features at the
time of serum sampling are illustrated in Table 1 (left
column). In particular, the Mayo score was calculated for all
cases at the time of blood sampling as the only validated
prognostic index in PBC [22].
Sera from patients (n=104, 60/104 females, median age
45, range 9–79) with other chronic liver diseases were used
as controls and included type-1 autoimmune hepatitis (AIH-
1, n=34), type-2 autoimmune hepatitis (AIH-2, n=12),
primary sclerosing cholangitis (PSC, n=12), hepatitis B
virus-related cirrhosis (n=9), and hepatitis C virus-related
cirrhosis (n=25) or active hepatitis (n=14).
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000) and
all subjects enrolled in the study provided written informed
consent after being informed about the nature of the study.
Serum AMA and ANA were first assayed by IIF on
sections of rat kidney, stomach and liver, and on HEp2
cells, respectively (INOVA, San Diego, CA, USA) in all
serum samples. Slides were analyzed independently by two
experienced pathologists (NB and FP) who were blinded to
the sample clinical diagnosis and the reported autoantibody
status. The results from the two observers were compared,
and in cases of discrepancy the slide was jointly reevaluated
until an agreement was reached.
A two-tier analysis was used for recombinant and
purified antigens. First, sera were assayed with an ELISA
screening test (PBC Screen, INOVA) based on the use of
three recombinant (pMIT3) and purified coating antigens
(gp210, Sp100) and the detection of IgG and IgA anti-
bodies. Second, PBC screen-positive sera were tested with
monospecific IgG ELISA assays (pMIT3, Sp100, and
gp210). To avoid Ig isotype discrepancies, cases that tested
positive at the PBC screen and negative at the IgG typing
tests were also tested using an IgA conjugate (INOVA).
Manufacturer cutoff values (25 units for all tests) were used
to determine positive results. All tests were performed in
duplicate at the Tolmezzo Laboratory of Clinical Pathology
by a single operator who was blind to the sera clinical
status; positive and negative control sera were included
throughout the study. One assay lot was used for all
samples to avoid lot-to-lot variability.
Comparison of the frequencies of laboratory and clinical
features between groups was made using the Mann–Whitney
U test for continuous variables and the chi-square analysis
for categorical variables. All analyses were two-tailed and P
values below 0.05 were considered statistically significant.
Statistical analysis was performed using SPSS for Windows,
version 11.5 (SPSS Inc, Chicago, IL, USA).
Results
We first confirmed that 100/100 IIF–AMA-negative sera
tested negative at IIF on rodent tissues. Similarly, none of
the 104 control sera tested positive for AMA at IIF. When
ANA were analyzed on HEp-2 cells, 13/100 and 23/100
IIF–AMA-negative PBC sera were positive for rim-like and
multiple nuclear dots patterns, respectively. As somehow
expected, 9/100 IIF–AMA-negative PBC sera manifested a
granular cytoplasmic AMA-like pattern on HEp-2 cells.
Among control sera, 2/104 manifested a multiple nuclear
dots ANA pattern.
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Among IIF–AMA-negative PBC sera, 43/100 tested
positive at the PBC Screen assay. When single antigens
were used, 11/100 sera recognized pMIT3 alone (includ-
ing 3 sera with only IgA reactivity), 8/100 gp210 only,
and 17/100 Sp100. Seven of 100 sera reacted against two
antigens as follows: one against pMIT3 and gp210 and
six against pMIT3 and Sp100. The pMIT3 reactivity was
overall observed in 18/100 (18%) of IIF–AMA-negative
PBC sera while anti-gp210 and anti-Sp100 antibodies
were positive in 9/100 and 23/100 PBC cases, respec-
tively. Among control sera, six tested positive at the PBC
Screen (four reacting against pMIT3 and 2 against
Sp100); once the serum code was broken, these sera
were found to be from patients with AIH-1 and a chart
review confirmed the diagnosis in all cases 1 year after
the serum was obtained. The PBC screen test had a
sensitivity of 43% among IIF–AMA-negative PBC sera
(subdivided into 18% for pMIT3, 9% for gp210, and
23% for Sp100 when single antigens were used) while
the test cumulative specificity was 94.2%. Concordance
between the ANA pattern on HEp-2 cells and specific
Sp100 and gp210 ELISA results in AMA-negative
subjects was 92% for nuclear dots and Sp100 and 99%
for nuclear rim and gp210 (Table 2). Of the nine sera that
showed a cytoplasmic mitochondrial-like pattern on the
HEp-2 cells but were IIF–AMA-negative on rodent
tissues, all were positive for PBC-screen and MIT3.
When IIF–AMA-negative PBC cases were arrayed
according to the PBC Screen reactivities (Table 1), we
observed that serum positivity did not identify a clinically
relevant subgroup of patients. One exception was the fact
that patients who tested negative at PBC screen were more
frequently taking ursodeoxycholic acid (UDCA) compared
to their positive counterpart (71% vs. 45%, P=0.005).
Similarly and following previous reports on the clinical
significance of PBC-specific ANA [17], we analyzed
whether the ANA and anti-gp210 status was associated
with a different clinical or biochemical phenotype (Table 3).
We demonstrated that patients who were ANA positive at
IIF had shorter disease duration (6 vs. 9 years) and were less
likely to be receiving UDCA treatment (16% vs. 43%)
compared to their ANA negative counterparts. The shorter
disease duration was also confirmed when anti-Sp100 was
analyzed. Quite surprisingly, no difference could be observed
in any of the included clinical features when patients were
classified according to their serum anti-gp210 status.
Table 2 Concordance of IIF-ANA findings (subdivided into multiple
nuclear dots, MND, and rim-like) with the purified antigens gp210,
Sp100 in 100 IIF–AMA-negative patients with PBC
MND ANA Rim-like ANA
+ − + −
Sp100 + 19 4
– 4 73
gp210 + 12 0
– 1 87
Concordance 92% 99%
Table 1 Clinical and biochemical features of IIF–AMA-negative PBC cases enrolled in the study according to their IIF and recombinant antigen
autoantibody status
IIF–AMA-negative (n=100) PBC screen positive (n=44) PBC screen negative (n=56) P value
Female sex (n) 90 40 50 0.7
Age (years) 61 (37–98) 57 (37–80) 62 (42–98) 0.3
Disease duration (years) 7 (1–31) 6 (1–26) 8 (1–31) 0.2
UDCA treatment (n) 60 (60%) 20 (45%) 40 (71%) 0.005
Encephalopathy (n) 2 (2%) 1 (2.3%) 1 (1.8%) 0.8
Ascites (n) 7 (7%) 4 (9.1%) 3 (5.3%) 0.5
Digestive bleeding (n) 2 (2%) 1 (2.3%) 1 (1.8%) 0.8
Alkaline phosphatase (UI/L) 150 (22–2,943) 131 (27–2,943) 171 (22–812) 0.2
Alanine aminotransferase (UI/L) 36 (7–515) 33 (7–139) 39 (11–555) 0.3
γ−glutamyl transferase (U/L) 113 (14–1,822) 117 (14–1,822) 105 (14–765) 0.4
Total bilirubin (mg/dL) 0.7 (0.2–41.4) 0.6 (0.2–6.1) 0.7 (0.2–41.4) 0.2
Albumin (g/L) 4.0 (2.6–6.2) 4.0 (2.6–6.2) 4.0 (2.6–5.1) 0.9
Prothrombin time (%) 98 (62–100) 99 (70–100) 98 (62–100) 0.4
Mayo score 4.94 (1.89–10.93) 4.77 (1.89–8.01) 5.00 (2.89–10.93) 0.08
Stage I–II 54/79 (68%) 23/79 (29%) 31/79 (39%) 0.8
Continuous variables are expressed as median (range). P values refer to the comparison between PBC screen positive and negative cases
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The History of AMA in PBC
Following earlier reports of AMA association with PBC
[23], the pioneer work of Eric Gershwin [11] first
demonstrated that AMA are directed against components
of the 2-oxoacid dehydrogenase complex (2-OADC)
family, including the E2 subunis of the pyruvate dehydro-
genase complex (PDC-E2), the branched chain 2-oxo-acid
dehydrogenase complex (BCOADC-E2), and the oxogluta-
rate dehydrogenase complex, as well as the dihydrolipoa-
mide dehydrogenase-binding protein and the E1α subunit
of pyruvate dehydrogenase complex (PDC-E1α). The E2
subunits of the three enzymes manifest a significantly
protein homology and, from an evolutionary standpoint, 2-
OADC proteins are highly conserved across species [24]. In
all three major antigens, epitopes contain the peptide motif
aspartic acid-lysine-arginine, with lipoic acid covalently
bound to the lysine (K) residue. The role of lipoic acid in
the epitope recognition by AMA is unclear but accumulat-
ing evidence supports a necessary role for this residue in
antibody recognition [25] while possibly being prone to
xenobiotic modifications as lipoic acid is exposed on the
outer surface [26–29] thus explaining the environmental
influence on disease onset and the proposed geoepidemiol-
ogy [30]. From a clinical standpoint, “autoimmune chol-
angitis” was first coined to indicate AMA-negative PBC
cases with detectable serum ANAwhile a broader definition
has been later suggested more recently to indicate the
presence of serum ANA and/or smooth muscle positivity
and/or hypergammaglobulinemia, serum AMA negativity
by IIF, biochemical and/or histological features of cholestatic
and hepatocellular injury, after chronic viral, metabolic, or
toxic liver disease have been ruled out [31]. Consensus is still
awaited on this issue and should be sought to avoid
misunderstanding in the clinical and histological evaluation
of patients with chronic biliary diseases.
The Present of AMA in PBC
We herein describe for the first time that a new commer-
cially available autoantibody array including the three
recombinant AMA and two major disease-specific ANA
autoantigens allows detecting PBC-specific autoantibodies
in 43% of a large series of sera-proven AMA-negative at
IIF. Of note, these data were gathered from 100 IIF–AMA-
negative sera, estimated to represent approximately 1,000
patients with PBC.
The diagnosis of PBC remains significantly dependent
on the presence of serum AMA, given that these represent
highly specific disease markers [32] and that liver histology
is associated with a low predictive value [33]. Indeed, the
diagnosis of PBC is made when two out of threeTa
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internationally accepted criteria are fulfilled, i.e., presence
of serum anti-AMA, increased enzymes indicating chole-
stasis (i.e., alkaline phosphatase) for longer than 6 months,
and compatible or diagnostic liver histology. A classification
made by a British group [10] proposed a “probable”
diagnosis when two out of the three criteria (most often
AMA positivity and compatible liver histology in the
presence of normal liver enzymes) are present. Accordingly,
a “definite” diagnosis should be made only in the presence
of all three. This classification may be seen as strict since the
vast majority of asymptomatic AMA-positive individuals
(particularly when serum reactivities are found using
sensitive and specific methods) will eventually develop a
classic picture of PBC during follow-up. Moreover, patients
lacking detectable AMA, especially when IIF is used but
otherwise presenting signs and symptoms of PBC should be
regarded as affected by “AMA-negative PBC” (or autoim-
mune cholangitis) as they appear to follow a similar natural
history when compared to their AMA-positive counterparts
[6].
Given their high specificity and their early appearance
prior to disease manifestations [9], AMA is a crucial
hallmark for the diagnosis of PBC as their positivity, along
with elevated cholestasis markers, allows a definitive
diagnosis [33]. While AMA can be regarded as the most
specific autoantibodies in the field of autoimmunity it is
quite frustrating that as many as 15% of patients with PBC
[6] do not manifest antimitochondrial reactivity when tested
by IIF, the routine method for autoantibody testing. For
these reasons, chipping away at the minority of PBC cases
in which serum AMA cannot be detected is of seminal
importance for the clinical diagnosis and management of
patients and for clinical epidemiology. Following the
original cloning of the autoantigen [11], the introduction
of recombinant AMA antigens [12, 34, 35] and the report
that a significant subgroup of patients with PBC manifest
disease-specific serum ANA [17, 36] has led to the
possibility that the AMA-negative subgroup may indeed
be rapidly overcome. The current IIF limitations have major
implications in the determination of pathogenetic role for
AMA as well as for the diagnostic workup and these
implications will be discussed in light of the data presented
herein.
First, data on the importance of sensitive AMA testing in
PBC influence both the diagnosis and management sides of
medical practice. Even in the absence of longitudinal data
from large population-based studies, AMA is believed to
appear in asymptomatic individuals decades prior to the
onset of PBC [8]. Metcalf et al. [8] reported that 76% of
asymptomatic individuals with serum AMA will eventually
develop symptoms of PBC over an 11- to 24-year follow-
up period. These observations have obvious implications
for the possible early diagnosis of PBC in which establish-
ing a medical treatment could lead to significant results
[37–39]. Second, an autoimmune pathogenesis of PBC is
widely accepted [40], yet several issues remain debated, as
in the case of the lack of clinical benefit from immune
suppressants or the absence of direct proof of AMA
pathogencity. Antibodies against various mitochondrial
enzymes can be frequently detected in patients with chronic
or acute liver diseases of other etiologies. In the case of
acute liver failure secondary to acetaminophen, however,
PBC-specific AMA are detected in 41% of patients thus
having possible implications for the mechanisms of PBC
onset [41]. On the other hand, other nonPBC AMA
responses are commonly directed at different epitopes than
in patients with PBC and have led to significant inaccura-
cies regarding the specificity of the AMA response. Serum
AMA include all three major immunoglobulin isotypes, i.e.,
IgG, IgM, and IgA with no major differences in epitope
specificity or diagnostic significance. AMA has been
detected also in bile, saliva, and urine from affected
individuals [42–45]; their relevance to PBC pathogenesis
remains unknown although the hypothesis of a direct IgA
role in the bile duct injury is fascinating [46].
In both these issues, our data are of significant
importance as we strongly support that AMA-negative
patients with PBC are progressively reducing in proportion
with obvious implications to the AMA pathogenic role.
Following a multicenter effort, we gathered the largest
reported population of patients with PBC who tested
negative for AMA using the IIF method on rodent tissues.
First, we evaluated whether the use of new ELISA tests for
detection of antibodies to MIT3, gp210 and Sp100 could
enable a diagnosis of definite PBC in AMA–IIF-negative
subjects. The use of a screening test that includes the hybrid
recombinant MIT3 and the Sp100 and g210 antigens
proved to be superior to IIF because it has greater
diagnostic sensitivity. In fact, all but two of the AMA–
IIF-positive patients and almost half of the AMA–IIF-
negative patients tested positive to the PBC screen test.
Regarding antibodies against the MIT3 antigen, the higher
sensitivity of the ELISA test in AMA-positive subjects was
confirmed in this study, as already found in other studies
[12, 32]. Most importantly, our data confirmed recent
reports from a large multicenter study that also included a
subgroup of the PBC sera investigated in the present work
[20]. Although the data warrant prospective confirmation, a
putative diagnostic algorithm could include an ELISA test
based on pMIT3 might as a confirmation test for positive
results obtained by the screening test. Specificity remains a
major issue for screening tests, as well illustrated by celiac
disease [47]. In the case of ELISA PBC screen test and
MIT3 specificity rates were 94.2% and 96.2%, respectively.
Of note, six control sera (from patients with type 1 AIH)
tested negative to AMA–IIF but positive to ELISA assays
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and were considered falsely positive because, at the time of
testing and in 1 year follow-up, there were no clinical
manifestations or biochemical signs of PBC. However, the
possibility of a subsequent appearance of overlap syndrome
features should not be overlooked [48]. We failed to
determine significant differences between AMA-positive
and AMA-negative patients in terms of epidemiological,
clinical, or biochemical features, thus confirming what has
already been observed [6], that is, that the presence of
AMA has diagnostic significance but does not influence the
clinical course of patients with PBC. Based on our current
knowledge, thus is not surprising. Although highly specific
for PBC, AMA do not predict the clinical phenotype nor
the prognosis of patients, similar to what has been observed
with the vast majority of autoantibodies in other autoim-
mune diseases, with the possible exception of anti-dsDNA
and lupus-associated nephritis [49]. This lack of clinical
correlation raises the long-standing issue of AMA patho-
genetic role in PBC that is well represented by recent
animal data on cholangitis improvement following B cell
depletion [50] or the AMA persistence following liver
transplantation [51]. Of interest, experimental data support
the hypothesis that the unique apoptotic features of bile
duct cells [52] concur with AMA to determine the disease
tissue specificity in a macrophage-dependent fashion [53].
It was first demonstrated that PDC-E2 remains intact and
retains its immunogenicity during cholangiocyte apoptosis,
secondary to a cell-specific lack of glutathionylation of
biliary epithelial cells [54]. The intact PDC-E2 in apoptotic
blebs (i.e., apotopes) could be then uptaken by local antigen
presenting cells and transferred to regional lymph nodes for
priming of cognate T cells thus initiating PBC [52].
The issue of ANA reactivity in PBC warrants further
discussion [55]. Only two previous studies investigated the
diagnostic of serum AMA using an ELISA method [56, 57],
both on smaller numbers of patients. One study [57] on 13
sera reported sensitivity and specificity rates of 38% and
94% for Sp100 and of 31% and 99% for gp210 while the
other included 22 patients [56] with sensitivity and specific-
ity rates of 55% and 99.2% for Sp100 and 45% and 100%
for gp210. Our larger series was characterized by lower
sensitivity (23% for Sp100, 9% for gp210) while specificity
rates were comparable (98% for Sp100 and 100% for
gp210). Quite surprisingly, our cross-sectional data could
not recapitulate the reported clinical differences based on
PBC-specific ANA reactivity [58] although different antigen
preparation could account for these discrepancies.
The Future of AMA in PBC
The advent of recombinant antigens [12] and new auto-
mated high-throughput methods paved the way to new tools
for AMA detection in PBC cases but most studies are
indeed performed in established series rather than in the
general population to discriminate the assay specificity
[59]. The Davis group proposed a novel bead-based assay
that utilizes recombinant antigens to further reduce the
prevalence of AMA-negative sera among otherwise estab-
lished PBC cases [35]. The proposed method improves the
sensitivity associated with spatial presentation, essential for
conformational epitopes, while allowing the detection of
multiple antigens at once in a small amount of serum [60–
62]. The assay has important advantages compared to
previous methods due to the possibility to use a large and
variable number of individual bead sets and of custom-
ization to include not only autoantibodies but possibly other
serum markers of immunity or inflammation. Moreover, the
proposed tool incorporates the advantages of a fully
automated procedure to significantly reduce operator
variability and maximizes standardization. Recombinant
antigens, i.e., PDC-E2, BCOADC-E2, OADC-E2, were
purified, applied to the activated beads, and assayed in a
standardized manner with a large series of PBC sera [63].
The technological improvement was also reflected in the
AMA detection in previously nonreactive sera. Six of these
sera (20%) reacted with at least one antigen and 10% with
more than one using our bead-based assay, thus making the
possibility of a structural bias unlikely. Moreover, AMA
titers in these previously negative sera often reaching levels
similar to other highly positive sera in some cases, thus
further suggesting the importance of conformation in
determining serum reactivities. One interesting observation
that resulted from the analysis of data is that all of the sera
that proved AMA-positive with the new assay were also
ANA-positive at IIF; a feature shared only by 48% of the
remaining AMA negatives whose prevalence appears
similar to previous reports and the reasons for this
discrepancy remain to be elucidated. Nevertheless, this
method is characterized by high costs and is thus poorly
applicable in clinical routine tests. For this reason, it is
necessary to determine whether more readily available tools
are capable to increase the diagnostic significance of AMA
and ANA tests in everyday clinical practice and in the case
of high a priori suspicion. We report herein the results of
the clinical use of a commercially available PBC autoan-
tibody test in a large cohort of IIF–AMA negative sera from
patients with an established diagnosis of PBC. While we
encourage the development of a prospective study, our data
support the view that AMA-negative PBC sera represent
the current laboratory limitations thus pointing toward the
overcoming of a probable diagnosis of PBC. Finally, we
foresee that new biological markers such as microRNA
[64], genetic polymorphisms [65, 66], or epigenetics [67,
68] may prove of significant importance in the future of
PBC diagnosis and management.
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